Veracyte reported preliminary Q4 revenue between $138 million and $140 million (16–18% growth) and full‑year 2025 revenue of $515–517 million, driven by testing volume gains. The diagnostic firm expects 45,500 tests in Q4 and provided 2026 revenue guidance of $570–582 million (10–13% growth). Management attributed the results to expansion of testing services and will present updated outlook at the JP Morgan healthcare conference.